The Rise in Autism and Emergence of Leucovorin as a Targeted Metabolic Intervention

The global prevalence of Autism Spectrum Disorder (ASD) has increased significantly over the past two decades, with epidemiological surveillance from the U.S. Centers for Disease Control and Prevention documenting a rise in estimated prevalence from 1 in 151 children in 2000 to 1 in 31 in 2025. This upward trajectory has been paralleled by expansive yet inconclusive research into diverse etiological factors, including polygenic risk, epigenetic modifiers, and environmental influences, without the identification of a singular pathophysiological mechanism. A recent U.S. federal initiative has catalyzed discourse by framing this increase as a public health priority and announcing the Food and Drug Administration’s approval of leucovorin (folinic acid) for ASD associated with cerebral folate deficiency (CFD). This regulatory action refocuses attention on biologically defined ASD subtypes (in particular, those that present with folate receptor autoantibodies) and metabolically targeted therapeutic strategies.

ASD is a heterogeneous neurodevelopmental condition characterized by core deficits in social communication and the presence of restricted, repetitive behaviors. Despite extensive investigation into genetic susceptibilities, metabolic disturbances, and environmental contributions, the integrative pathophysiology underlying its full phenotypic spectrum remains elusive. In response to rising prevalence estimates, a 2025 federal policy announcement included a consequential regulatory development: the FDA approval of folinic acid, otherwise known as leucovorin, for a subset of ASD cases. This decision underscores a paradigm shift toward precision medicine in neurodevelopmental disorders, moving from purely behavioral management to the consideration of underlying metabolic dysregulation.

Folate (vitamin B₉) is a critical cofactor in one-carbon metabolism, a network of biochemical reactions essential for DNA synthesis and repair, cellular proliferation, and the production of S-adenosylmethionine (SAM), the primary methyl donor for epigenetic regulation and neurotransmitter synthesis. Perturbations in folate metabolism are well-established in neurodevelopmental pathology, most notably in neural tube defects. Epidemiological data support that periconceptional folate supplementation reduces general population risk for ASD, implicating folate pathways in its neurobiology.

Transport of folate into the central nervous system is an active, receptor-mediated process. Folate receptor-alpha (FRα) facilitates uptake across the choroid plexus. A subset of individuals, however, produce autoantibodies against FRα (FRAAs), impairing transport and leading to a form of cerebral folate deficiency (CFD)—a condition defined by low concentrations of 5-methyltetrahydrofolate (5-MTHF) in the cerebrospinal fluid despite normal folate levels in the blood. The increased prevalence of FRAAs in probands with ASD and their first-degree relatives suggests an immune-mediated mechanism disrupting central folate homeostasis, potentially contributing to neurodevelopmental dysfunction in this subgroup. Folate receptor autoantibodies are diagnosed with the FRAT^® test.

Folinic acid (5-formyl-tetrahydrofolate) is a reduced, bioactive folate derivative. Its therapeutic relevance lies in its ability to bypass the dihydrofolate reductase (DHFR) step required for the activation of synthetic folic acid, thereby directly replenishing the intracellular tetrahydrofolate pool. It is absorbed via the proton-coupled folate transporter (PCFT) and the reduced folate carrier (RFC/SLC19A1) and utilizes FRα-mediated endocytosis for CNS entry, making it a rational intervention for circumventing FRAA-associated transport blockade.

Clinical evidence, though preliminary, indicates a potential therapeutic niche. A randomized, double-blind, placebo-controlled trial by Frye et al. (2018) demonstrated that high-dose folinic acid supplementation significantly improved core symptoms of verbal communication and adaptive behavior in children with ASD, with treatment effects most pronounced in FRAA-positive participants. Subsequent studies, including the EFFET trial in France, have reported corroborative improvements in Autism Diagnostic Observation Schedule (ADOS) scores and favorable tolerability profiles. Pharmacogenetic analyses further suggest that treatment response may be modulated by polymorphisms in genes such as MTHFR and MTR, highlighting the interplay between intervention and individual genetic architecture.

Current data posit that folinic acid may ameliorate specific symptom domains in a biologically defined ASD subset, namely individuals with FRAAs seropositivity or biochemically confirmed CFD. FRAAs can be detected with the use of the FRAT^® test. It is imperative to contextualize this within the framework of the FDA’s labeled indication, which specifies treatment for ASD with comorbid CFD, not for ASD as a broad diagnostic entity.

Significant methodological limitations constrain generalizability. Existing studies are characterized by modest sample sizes, heterogeneous dosing regimens, and short-term follow-up periods. Consequently, large-scale, multicenter, randomized controlled trials with extended observation windows are recommended to definitively establish long-term efficacy, optimal dosing protocols, and validated biomarker predictors of response.

The FDA’s authorization of folinic acid represents a pivotal, if narrowly focused, advancement in the conceptualization of ASD therapeutics, emphasizing metabolic and immune pathways. However, ASD is a multifactorial condition for which a universal monotherapy is unlikely. This development mandates rigorous scientific communication: while folinic acid is a promising targeted intervention for a specific pathophysiological subgroup, it is not a panacea. Future progress hinges on disciplined, data-driven research to translate this precision medicine approach into validated clinical practice, ensuring that patients and families receive interventions based on robust evidence rather than speculative enthusiasm.

• Shaw KA, Williams S, Patrick ME, et al. Prevalence and early identification
  of autism spectrum disorder among children aged 4 and
  8 years—autism and developmental disabilities monitoring network,
  16 sites, United States, 2022. MMWR Surveill Summ. 2025;74(2):1-22.
• Levine SZ, Kodesh A, Viktorin A, et al. Association of maternal use
  of folic acid and multivitamin supplements in the periods before
  and during pregnancy with the risk of autism spectrum disorder
  in offspring. JAMA Psychiatry. 2018;75(2):176-184.
• Frye RE, Sequeira JM, Quadros EV, James SJ, Rossignol DA. Cerebral
  folate receptor autoantibodies in autism spectrum disorder.
  Mol Psychiatry. 2013;18(3):369-381.
• Quadros EV, Sequeira JM, Brown WT, et al. Folate receptor autoantibodies
  are prevalent in children diagnosed with autism spectrum
  disorder, their normal siblings and parents. Autism Res. 2018;11(5):707-712
• Ramaekers VT, Hausler M, Opladen T, Heimann G, Blau N. Psychomotor
  retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution. Neuropediatrics. 2002;33(6):301-308.